A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Trial Profile

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CELESTIAL
  • Sponsors Exelixis
  • Most Recent Events

    • 16 Oct 2017 According to an Exelixis media release, based on results from this trial, Exelixis plans to submit a supplemental New Drug Application (sNDA) to the US FDA in the first quarter of 2018. Detailed results from this trial will be submitted for presentation at a future medical conference.
    • 16 Oct 2017 According to an Ipsen media release, status changed from recruiting to active, no longer recruiting in September 2017.
    • 16 Oct 2017 Primary endpoint (Overall Survival (OS)) has been met, according to an Ipsen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top